BGSF exhibits severe financial distress, as evidenced by a Piotroski F-Score of 2/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises bankruptcy risk concerns. The company reports negative profitability across all key metrics—ROE (-17.69%), ROA (-5.62%), and a -12.25% profit margin—while revenue has collapsed by 65.8% YoY. Despite a seemingly low Price/Book (1.49) and modest Price/Sales (0.77), the company’s deteriorating earnings trajectory and lack of sustainable growth undermine valuation appeal. Insider activity is neutral with no recent trades, and analyst coverage is absent, signaling minimal institutional interest. The stock’s recent 151.7% 1-year return appears speculative, driven by momentum rather than fundamentals.